Sills Cummis & Gross Represents Optherion In $37 Million Financing

Thursday, November 1, 2007 - 01:00

Optherion, Inc., a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced recently that it has raised $37 million in start up financing. Sills Cummis & Gross attorneys Ira A. Rosenberg, Lori M. Waldron, Laurajane B. Kastner and James A. Dempsey represented Optherion in connection with this financing.

Optherion's focus is to develop disease-modifying therapies to prevent loss of vision in patients with dry AMD, the leading cause of blindness in people over 60 in the developed world, as well as a portfolio of tests that predict, diagnose and monitor progression of the disease.

Among the sources of capital for the financing are: Quaker BioVentures, Philadelphia; Domain Associates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; Pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA, and GE Healthcare Financial Services, Chicago, IL.